MX359403B - Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr, y opcionalmente un inhibidor de pi3k-alfa. - Google Patents
Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr, y opcionalmente un inhibidor de pi3k-alfa.Info
- Publication number
- MX359403B MX359403B MX2015001732A MX2015001732A MX359403B MX 359403 B MX359403 B MX 359403B MX 2015001732 A MX2015001732 A MX 2015001732A MX 2015001732 A MX2015001732 A MX 2015001732A MX 359403 B MX359403 B MX 359403B
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- optionally
- pi3k
- egfr
- raf
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261680473P | 2012-08-07 | 2012-08-07 | |
| PCT/US2013/053619 WO2014025688A1 (en) | 2012-08-07 | 2013-08-05 | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015001732A MX2015001732A (es) | 2015-06-03 |
| MX359403B true MX359403B (es) | 2018-09-26 |
Family
ID=48980368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015001732A MX359403B (es) | 2012-08-07 | 2013-08-05 | Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr, y opcionalmente un inhibidor de pi3k-alfa. |
Country Status (39)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013299841B8 (en) * | 2012-08-07 | 2017-01-05 | Array Biopharma Inc. | Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor |
| AU2014233805B2 (en) | 2013-03-21 | 2018-10-18 | Array Biopharma Inc. | Combination therapy comprising a B-Raf inhibitor and a second inhibitor |
| WO2015145388A2 (en) * | 2014-03-27 | 2015-10-01 | Novartis Ag | Methods of treating colorectal cancers harboring upstream wnt pathway mutations |
| ES2686549T3 (es) * | 2014-06-16 | 2018-10-18 | Worldwide Innovative Network | Método para seleccionar una triterapia personalizada para el tratamiento del cáncer |
| WO2016193955A1 (en) * | 2015-06-04 | 2016-12-08 | Giorgio Stassi | Combinations of kinase inhibitors for treating colorectal cancer |
| JP2018526375A (ja) * | 2015-08-28 | 2018-09-13 | ノバルティス アーゲー | 組み合わせ療法 |
| US10328065B2 (en) | 2015-08-28 | 2019-06-25 | Novartis Ag | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer |
| WO2017066664A1 (en) * | 2015-10-16 | 2017-04-20 | Millennium Pharmaceuticals, Inc. | Combination therapy including a raf inhibitor for the treatment of colorectal cancer |
| WO2017210538A1 (en) * | 2016-06-03 | 2017-12-07 | Giordano Caponigro | Pharmaceutical combinations |
| EP3515446B1 (en) | 2016-09-19 | 2023-12-20 | Novartis AG | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
| DK3618875T3 (da) | 2017-05-02 | 2023-07-10 | Novartis Ag | Kombinationsterapi omfattende en raf-inhibitor og trametinib |
| WO2019026007A1 (en) * | 2017-08-03 | 2019-02-07 | Novartis Ag | THERAPEUTIC ASSOCIATION OF THIRD GENERATION TYFRSINE KINASE INHIBITOR AND RAF INHIBITOR |
| HUE066335T2 (hu) | 2018-10-05 | 2024-07-28 | Annapurna Bio Inc | Vegyületek és készítmények APJ receptor aktivitáshoz kapcsolódó állapotok kezelésére |
| TWI849043B (zh) * | 2019-01-25 | 2024-07-21 | 英屬開曼群島商百濟神州有限公司 | B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途 |
| WO2020164997A1 (en) * | 2019-02-12 | 2020-08-20 | Bayer Aktiengesellschaft | Combination of pi3k-inhibitors |
| KR102881316B1 (ko) | 2019-05-13 | 2025-11-05 | 노파르티스 아게 | 암 치료를 위한 raf 억제제로서의 n-(3-(2-(2-하이드록시에톡시)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-2 (트리플루오로메틸)이소니코틴아미드의 새로운 결정질 형태 |
| JPWO2023145530A1 (cg-RX-API-DMAC7.html) * | 2022-01-27 | 2023-08-03 | ||
| CA3257280A1 (en) | 2022-05-25 | 2023-11-30 | Msd International Gmbh | COMBINATION OF A BRAF INHIBITOR, AN EGFR INHIBITOR AND A PD-1 ANTAGONIST FOR THE TREATMENT OF COLORECTAL CANCER MSI-H/DMMR, WITH BRAF V600E MUTATION |
| CN120359031A (zh) * | 2022-09-26 | 2025-07-22 | 马布可尔公司 | 用于治疗癌症的b-raf抑制剂和抗egfr抗体的组合 |
| WO2025003956A1 (en) | 2023-06-30 | 2025-01-02 | Pfizer Inc. | High drug loading formulations of encorafenib |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| DK2139484T3 (da) | 2007-04-10 | 2013-10-21 | Exelixis Inc | Fremgangsmåder til behandling af cancer ved brug af pyridopyrimidinon-inhibitorer af PI3K-alfa |
| UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| AU2010289794B2 (en) * | 2009-08-24 | 2014-10-02 | Genentech, Inc. | Determining sensitivity of cells to B-Raf inhibitor treatment by detecting Kras mutation and RTK expression levels |
| AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| JP2013507442A (ja) * | 2009-10-12 | 2013-03-04 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 組合せ |
| US20120045433A1 (en) | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
| TR201802943T4 (tr) * | 2010-11-08 | 2018-03-21 | Novartis Ag | (S)-pirolidin-1,2-dikarboksilik asit 2-amid 1-({4-metil-5-[2-(2,2,2-trifloro-1,1-dimetil-etil)-piridin-4-il]-tiyazol-2-il}amid)'in egfr'ye bağlı hastalıkların veya egfr familya üyelerini hedefleyen ajanlara karşı direnç edinmiş hastalıkların tedavisinde kullanımı. |
| WO2013070998A1 (en) | 2011-11-10 | 2013-05-16 | Memorial Sloan-Kettering Cancer Center | TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES |
| CA2855243C (en) * | 2011-11-11 | 2020-04-14 | Novartis Ag | Method of treating a proliferative disease |
| AU2013299841B8 (en) * | 2012-08-07 | 2017-01-05 | Array Biopharma Inc. | Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor |
-
2013
- 2013-08-05 AU AU2013299841A patent/AU2013299841B8/en active Active
- 2013-08-05 IN IN450DEN2015 patent/IN2015DN00450A/en unknown
- 2013-08-05 LT LTEP13748243.6T patent/LT2882440T/lt unknown
- 2013-08-05 ES ES13748243T patent/ES2717911T3/es active Active
- 2013-08-05 UA UAA201500424A patent/UA115786C2/uk unknown
- 2013-08-05 JP JP2015526606A patent/JP6342396B2/ja active Active
- 2013-08-05 PE PE2015000130A patent/PE20150673A1/es not_active Application Discontinuation
- 2013-08-05 TR TR2019/04980T patent/TR201904980T4/tr unknown
- 2013-08-05 PE PE2019001539A patent/PE20191655A1/es unknown
- 2013-08-05 CA CA2879548A patent/CA2879548C/en active Active
- 2013-08-05 PL PL13748243T patent/PL2882440T3/pl unknown
- 2013-08-05 RS RS20190351A patent/RS58734B1/sr unknown
- 2013-08-05 US US14/419,256 patent/US9474754B2/en active Active
- 2013-08-05 MY MYPI2015000102A patent/MY176031A/en unknown
- 2013-08-05 EP EP19159506.5A patent/EP3574904A1/en active Pending
- 2013-08-05 WO PCT/US2013/053619 patent/WO2014025688A1/en not_active Ceased
- 2013-08-05 PT PT13748243T patent/PT2882440T/pt unknown
- 2013-08-05 HU HUE13748243A patent/HUE042877T2/hu unknown
- 2013-08-05 EP EP13748243.6A patent/EP2882440B1/en active Active
- 2013-08-05 CN CN201380042229.5A patent/CN104519887B/zh active Active
- 2013-08-05 EA EA201590332A patent/EA028420B1/ru not_active IP Right Cessation
- 2013-08-05 MX MX2015001732A patent/MX359403B/es active IP Right Grant
- 2013-08-05 HR HRP20190537TT patent/HRP20190537T1/hr unknown
- 2013-08-05 SI SI201331387T patent/SI2882440T1/sl unknown
- 2013-08-05 SG SG11201500321YA patent/SG11201500321YA/en unknown
- 2013-08-05 HK HK15110834.2A patent/HK1211831A1/xx unknown
- 2013-08-05 NZ NZ703940A patent/NZ703940A/en unknown
- 2013-08-05 DK DK13748243.6T patent/DK2882440T3/da active
- 2013-08-05 KR KR1020157002982A patent/KR102112885B1/ko active Active
- 2013-08-05 AR ARP130102776A patent/AR092045A1/es not_active Application Discontinuation
- 2013-08-06 TW TW102128165A patent/TWI607754B/zh active
- 2013-08-06 JO JOP/2013/0236A patent/JOP20130236B1/ar active
-
2015
- 2015-01-19 TN TNP2015000027A patent/TN2015000027A1/fr unknown
- 2015-01-26 IL IL236934A patent/IL236934B/en active IP Right Grant
- 2015-02-04 MA MA37829A patent/MA37829A1/fr unknown
- 2015-02-04 PH PH12015500246A patent/PH12015500246B1/en unknown
- 2015-02-06 GT GT201500025A patent/GT201500025A/es unknown
- 2015-02-06 CL CL2015000294A patent/CL2015000294A1/es unknown
- 2015-02-06 CO CO15024921A patent/CO7200273A2/es unknown
- 2015-03-06 EC ECIEPI20158695A patent/ECSP15008695A/es unknown
-
2018
- 2018-02-09 JP JP2018022248A patent/JP6595024B2/ja active Active
-
2019
- 2019-04-30 CY CY20191100461T patent/CY1122143T1/el unknown
- 2019-09-25 JP JP2019174353A patent/JP6974669B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX359403B (es) | Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr, y opcionalmente un inhibidor de pi3k-alfa. | |
| AR091876A1 (es) | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas | |
| CY1124311T1 (el) | Παρεμποδιστες dna-pk | |
| CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
| CO7350624A2 (es) | Inhibidores de la tirosina-quinasa de bruton | |
| NI201000105A (es) | Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada. | |
| MX2016004580A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| MX2013006591A (es) | Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas. | |
| AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
| DOP2015000108A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasas | |
| CL2015002807A1 (es) | Terapia de combinación | |
| EA201490194A1 (ru) | Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака | |
| CL2015000744A1 (es) | Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer. | |
| MX366317B (es) | Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias. | |
| MX2015009045A (es) | Composiciones y metodos para tratar el dolor severo. | |
| NI201400112A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| DOP2015000070A (es) | Procedimientos para fabricar medicamentos útiles para tratar artritis reumatoide | |
| CL2018003421A1 (es) | Combinaciones farmacéuticas. | |
| CO7151543A2 (es) | Combinaciones terapéuticas y métodos para tratar el melanoma | |
| CL2012002858A1 (es) | Combinación farmacéutica que comprende 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencilamidazol-2-il-quinolin-2-ona y al menos un inhibidor de mtor; método de tratamiento; y uso para el tratamiento y la prevención de una enfermedad proliferativa tal como cáncer de mama, tumores neuroendocrinos y linfonas, entre otras. | |
| CO7111317A2 (es) | Método para el tratamiento de enfermedades ginecológicas | |
| EA201500232A1 (ru) | Три(гетеро)арилпиразолы и их применение | |
| CR20110687A (es) | Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cancer | |
| UY35033A (es) | Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa | |
| AR105142A1 (es) | Métodos de tratamiento del glioblastoma multiforme con terapia de células t |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |